2023-508171-36-00CompletedPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07293893 are Tolerated and Act in the Body of Healthy Adults.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Jun 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 7 Nov 2023
- Start date
- 15 Dec 2023
- Lead sponsor
- Pfizer Inc.
- EU CT number
- 2023-508171-36-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Clinical Research Unit | Brussels | Belgium | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.